Renaissance Technologies LLC Has $42.42 Million Position in iRadimed Corporation $IRMD

Renaissance Technologies LLC lessened its holdings in shares of iRadimed Corporation (NASDAQ:IRMD) by 3.4% during the 1st quarter, Holdings Channel.com reports. The firm owned 440,712 shares of the medical equipment provider’s stock after selling 15,700 shares during the period. Renaissance Technologies LLC’s holdings in iRadimed were worth $42,423,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Tudor Investment Corp ET AL bought a new stake in iRadimed during the 3rd quarter worth about $666,000. SG Americas Securities LLC raised its stake in shares of iRadimed by 88.6% in the fourth quarter. SG Americas Securities LLC now owns 70,391 shares of the medical equipment provider’s stock worth $6,848,000 after acquiring an additional 33,072 shares during the last quarter. Baader Bank Aktiengesellschaft bought a new position in shares of iRadimed in the fourth quarter worth about $595,000. Bridge City Capital LLC lifted its position in shares of iRadimed by 19.4% during the fourth quarter. Bridge City Capital LLC now owns 70,854 shares of the medical equipment provider’s stock worth $6,893,000 after purchasing an additional 11,509 shares in the last quarter. Finally, RFG Advisory LLC acquired a new position in shares of iRadimed during the fourth quarter worth approximately $1,594,000. 92.34% of the stock is currently owned by institutional investors and hedge funds.

iRadimed Stock Up 0.6%

iRadimed stock opened at $95.08 on Tuesday. The business’s 50-day simple moving average is $94.29 and its 200 day simple moving average is $95.82. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of 51.96 and a beta of 0.90. iRadimed Corporation has a 12-month low of $56.15 and a 12-month high of $107.90.

iRadimed (NASDAQ:IRMD) last announced its quarterly earnings data on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.03. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.The firm had revenue of $21.98 million during the quarter, compared to analysts’ expectations of $21.32 million. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. As a group, sell-side analysts expect that iRadimed Corporation will post 1.52 EPS for the current year.

iRadimed Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, May 29th. Stockholders of record on Friday, May 15th were given a dividend of $0.20 per share. The ex-dividend date was Friday, May 15th. This represents a $0.80 annualized dividend and a dividend yield of 0.8%. iRadimed’s payout ratio is currently 43.72%.

Insider Buying and Selling at iRadimed

In related news, CEO Roger E. Susi sold 2,500 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $90.60, for a total value of $226,500.00. Following the transaction, the chief executive officer directly owned 2,162,500 shares in the company, valued at $195,922,500. This represents a 0.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 21,250 shares of company stock worth $1,836,403 over the last ninety days. Insiders own 34.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on IRMD. Weiss Ratings lowered shares of iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, May 20th. Freedom Capital raised iRadimed to a “strong-buy” rating in a report on Thursday, April 2nd. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, iRadimed currently has a consensus rating of “Buy” and a consensus target price of $120.00.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.